MX2018004043A - Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. - Google Patents
Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.Info
- Publication number
- MX2018004043A MX2018004043A MX2018004043A MX2018004043A MX2018004043A MX 2018004043 A MX2018004043 A MX 2018004043A MX 2018004043 A MX2018004043 A MX 2018004043A MX 2018004043 A MX2018004043 A MX 2018004043A MX 2018004043 A MX2018004043 A MX 2018004043A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty acids
- reversal
- disease
- prevention
- treatment
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 5
- 229930195729 fatty acid Natural products 0.000 title abstract 5
- 239000000194 fatty acid Substances 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 150000004665 fatty acids Chemical class 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title 1
- -1 keto fatty acids Chemical class 0.000 abstract 2
- WRADPCFZZWXOTI-BMRADRMJSA-N (9E)-10-nitrooctadecenoic acid Chemical compound CCCCCCCC\C([N+]([O-])=O)=C/CCCCCCCC(O)=O WRADPCFZZWXOTI-BMRADRMJSA-N 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 abstract 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236702P | 2015-10-02 | 2015-10-02 | |
| PCT/US2016/055206 WO2017059451A1 (en) | 2015-10-02 | 2016-10-03 | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004043A true MX2018004043A (es) | 2018-11-09 |
Family
ID=58428002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004043A MX2018004043A (es) | 2015-10-02 | 2016-10-03 | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10537541B2 (https=) |
| EP (1) | EP3355879A4 (https=) |
| JP (2) | JP2018529779A (https=) |
| KR (1) | KR20180098222A (https=) |
| CN (2) | CN108430466A (https=) |
| AU (2) | AU2016331314A1 (https=) |
| BR (1) | BR112018006687A2 (https=) |
| CA (1) | CA3000842A1 (https=) |
| CL (1) | CL2018000835A1 (https=) |
| CO (1) | CO2018004576A2 (https=) |
| CR (1) | CR20180246A (https=) |
| EA (1) | EA201890859A1 (https=) |
| HK (1) | HK1259031A1 (https=) |
| IL (2) | IL258476B2 (https=) |
| MX (1) | MX2018004043A (https=) |
| SG (1) | SG10201913953UA (https=) |
| WO (1) | WO2017059451A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102083787A (zh) * | 2008-05-01 | 2011-06-01 | 康普雷克萨公司 | 乙烯基取代的脂肪酸 |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| HRP20240082T1 (hr) | 2015-07-07 | 2024-03-29 | H. Lundbeck A/S | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti |
| IL258476B2 (en) * | 2015-10-02 | 2023-04-01 | Complexa Inc | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
| FI3801526T3 (fi) | 2018-05-25 | 2024-03-20 | Cardurion Pharmaceuticals Inc | 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja |
| EP3843737A4 (en) | 2018-08-31 | 2022-06-01 | Imara Inc. | PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE |
| CN111229117B (zh) * | 2018-11-29 | 2022-01-04 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
| CN111229120B (zh) * | 2018-11-29 | 2022-01-07 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
| FR3092968B1 (fr) * | 2019-02-22 | 2021-05-21 | Microphyt | Complement alimentaire |
| CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
| WO2021242758A1 (en) * | 2020-05-26 | 2021-12-02 | Imara Inc. | Improved nitro-fatty acid oral dose regimens |
| WO2023014748A1 (en) * | 2021-08-03 | 2023-02-09 | Imara Inc. | Nitrated fatty acids for the treatment of sickle cell disorders |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB587992A (en) | 1944-12-11 | 1947-05-12 | Charles William Scaife | Improvements in and relating to the production of organic nitrogen compounds |
| US3578687A (en) | 1968-01-30 | 1971-05-11 | Texaco Inc | Process for producing 4-nitroalkanoic acids |
| US3819561A (en) | 1970-10-23 | 1974-06-25 | Aerojet General Co | Wetting agents for non-aqueous dispersions |
| JPS5313608B2 (https=) | 1972-06-16 | 1978-05-11 | ||
| JPS5318013B2 (https=) | 1973-03-19 | 1978-06-13 | ||
| US4599430A (en) | 1981-12-21 | 1986-07-08 | The Standard Oil Company | Nitrogenation of hydrocarbons, including the production of maleimide |
| JPS62132804A (ja) | 1985-12-05 | 1987-06-16 | Aguro Kanesho Kk | 植物生長調節剤 |
| US5412137A (en) | 1993-06-07 | 1995-05-02 | Sandoz Ltd. | Process for preparing phosphinyloxy propanaminium inner salt derivatives |
| DE69524639T2 (de) | 1994-10-13 | 2002-08-08 | Peptech Ltd., North Ryde | Modifizierte mehrfach ungesättigte fettsäuren |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
| GB9618420D0 (en) | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
| KR100569319B1 (ko) | 1997-10-30 | 2006-04-07 | 모리시타 진탄 가부시키가이샤 | 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법 |
| WO2000009075A2 (en) | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| MXPA01009893A (es) | 1999-04-01 | 2003-07-28 | Esperion Therapeutics Inc | Compuestos con eter, composiciones y usos de estos. |
| AU5319499A (en) | 1999-07-22 | 2001-02-13 | Ivan L. Cameron | Fatty acids to minimize cancer therapy side effects |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
| US6346231B1 (en) | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
| US20010037598A1 (en) | 1999-12-14 | 2001-11-08 | Suppes Galen J. | Process for producing cetane improvers from triglycerides |
| JP4932116B2 (ja) | 2000-02-16 | 2012-05-16 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | アスピリン誘発脂質メディエータ |
| AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
| AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
| AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
| US20040006248A1 (en) | 2000-06-28 | 2004-01-08 | Zambon Group S.P.A | Process for the preparation of nitroalkenes |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| IL158322A0 (en) | 2001-04-18 | 2004-05-12 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| JPWO2002102364A1 (ja) | 2001-06-18 | 2004-09-30 | 山田 幸子 | ＰＰＡＲγ作動性医薬組成物 |
| US6998395B2 (en) | 2001-08-17 | 2006-02-14 | University Of Pittsburg, | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| GB0123961D0 (en) | 2001-10-05 | 2001-11-28 | Astrazeneca Ab | Process and intermediates |
| JP4652685B2 (ja) | 2001-11-06 | 2011-03-16 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物 |
| US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
| US20060100278A1 (en) | 2002-08-20 | 2006-05-11 | Cooper Garth J S | Dosage forms and related therapies |
| EP2384750A1 (en) | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| WO2005016864A1 (en) | 2003-07-29 | 2005-02-24 | The Arizona Disease Control Research Commission | Conjugated nitro alkene anticancer agents based on isoprenoid metabolism |
| US20050136103A1 (en) | 2003-09-17 | 2005-06-23 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| CA2554735A1 (en) | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| US8241670B2 (en) | 2004-04-15 | 2012-08-14 | Chiasma Inc. | Compositions capable of facilitating penetration across a biological barrier |
| US7776916B2 (en) * | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
| BRPI0513508B1 (pt) | 2004-07-19 | 2021-06-01 | Biocon Limited | Conjugados de insulina-oligômero, formulações e usos desses |
| EP1772149A1 (en) | 2004-07-27 | 2007-04-11 | Kowa Company. Ltd. | Drug for prevention or treatment of diabetes |
| WO2006055965A2 (en) | 2004-11-19 | 2006-05-26 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
| US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
| US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| WO2008008767A2 (en) | 2006-07-14 | 2008-01-17 | Cedars-Sinai Medical Center | Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer |
| JP2009545527A (ja) | 2006-07-19 | 2009-12-24 | リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド | 粘膜炎の治療用の組成物及び方法 |
| EP2120920A4 (en) | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE |
| EP2679224A1 (en) | 2007-08-01 | 2014-01-01 | University of Pittsburgh of the Commonwealth System of Higher Education | Nitro oleic acid modulation of type II diabetes |
| CA2699483A1 (en) | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
| EP2271929B1 (en) | 2008-04-18 | 2015-11-25 | The University of Utah Research Foundation | Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
| CN102083787A (zh) | 2008-05-01 | 2011-06-01 | 康普雷克萨公司 | 乙烯基取代的脂肪酸 |
| WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
| US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| WO2009155439A2 (en) | 2008-06-19 | 2009-12-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| JP2012513774A (ja) * | 2008-12-31 | 2012-06-21 | ニトロメガ コーポレーション | ニトロ脂肪酸を含有する栄養補助物 |
| US8937194B2 (en) * | 2008-12-31 | 2015-01-20 | Nitromega Corp. | Topical compositions containing nitro fatty acids |
| US20100286272A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications |
| US20100286257A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging |
| US20100286271A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Nitro-alkyl Compound Compositions |
| US20120136057A1 (en) | 2009-07-29 | 2012-05-31 | Phenomenome Discoveries Inc. | Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis |
| EP2459189A4 (en) | 2009-07-31 | 2013-01-16 | Univ Pittsburgh | FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS |
| WO2011041639A2 (en) | 2009-10-02 | 2011-04-07 | Miller Raymond A | Heteroatom containing substituted fatty acids |
| KR20120130078A (ko) | 2009-11-09 | 2012-11-28 | 메디비르 아베 | 신규한 1,3-옥사졸리딘 화합물 및 이의 레닌 억제제로서의 용도 |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| KR20130054249A (ko) * | 2010-03-15 | 2013-05-24 | 울리히 디에츠 | 공격적 치료 패턴의 치료, 진단 및 예방용 니트로카르복실산의 용도 |
| US8563609B2 (en) | 2010-05-13 | 2013-10-22 | Nitromega Corp. | Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline |
| JP2013534930A (ja) | 2010-06-28 | 2013-09-09 | コンプレクサ，インコーポレイテッド | 糖尿病を治療するための多成分調剤 |
| EP2744491B1 (en) | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
| US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
| DE102012008730A1 (de) * | 2011-12-02 | 2013-06-06 | Dr. Budz GmbH | Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung |
| EP2809317A4 (en) | 2012-02-03 | 2015-07-22 | Univ Pittsburgh | FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES |
| US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
| EP2994165A4 (en) | 2013-05-10 | 2017-01-04 | Nitromega Corp. | Nutritional or dietary supplements containing fatty acids and nitrite |
| WO2014204872A2 (en) | 2013-06-14 | 2014-12-24 | Complexa, Inc. | Composition and method for inhibition of pkng from mycobacterium tuberculosis |
| WO2015073527A1 (en) | 2013-11-12 | 2015-05-21 | Complexa, Inc. | Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions |
| WO2016161285A1 (en) * | 2015-04-02 | 2016-10-06 | Aobiome Llc | Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria |
| IL258476B2 (en) * | 2015-10-02 | 2023-04-01 | Complexa Inc | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
-
2016
- 2016-10-03 IL IL258476A patent/IL258476B2/en unknown
- 2016-10-03 CN CN201680070797.XA patent/CN108430466A/zh active Pending
- 2016-10-03 EP EP16852846.1A patent/EP3355879A4/en not_active Withdrawn
- 2016-10-03 MX MX2018004043A patent/MX2018004043A/es unknown
- 2016-10-03 CR CR20180246A patent/CR20180246A/es unknown
- 2016-10-03 JP JP2018536704A patent/JP2018529779A/ja not_active Withdrawn
- 2016-10-03 BR BR112018006687A patent/BR112018006687A2/pt not_active Application Discontinuation
- 2016-10-03 US US15/283,887 patent/US10537541B2/en not_active Expired - Fee Related
- 2016-10-03 CN CN202110744035.6A patent/CN113440506A/zh active Pending
- 2016-10-03 KR KR1020187012337A patent/KR20180098222A/ko not_active Ceased
- 2016-10-03 HK HK19101519.9A patent/HK1259031A1/zh unknown
- 2016-10-03 AU AU2016331314A patent/AU2016331314A1/en not_active Abandoned
- 2016-10-03 IL IL297844A patent/IL297844A/en unknown
- 2016-10-03 WO PCT/US2016/055206 patent/WO2017059451A1/en not_active Ceased
- 2016-10-03 CA CA3000842A patent/CA3000842A1/en not_active Abandoned
- 2016-10-03 SG SG10201913953UA patent/SG10201913953UA/en unknown
- 2016-10-03 EA EA201890859A patent/EA201890859A1/ru unknown
-
2018
- 2018-03-29 CL CL2018000835A patent/CL2018000835A1/es unknown
- 2018-04-27 CO CONC2018/0004576A patent/CO2018004576A2/es unknown
-
2019
- 2019-10-18 US US16/657,028 patent/US20200046669A1/en not_active Abandoned
-
2021
- 2021-03-19 US US17/207,380 patent/US20220000824A1/en not_active Abandoned
- 2021-07-14 AU AU2021205027A patent/AU2021205027A1/en not_active Abandoned
- 2021-08-27 JP JP2021139287A patent/JP2021183640A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021183640A (ja) | 2021-12-02 |
| CR20180246A (es) | 2018-11-22 |
| BR112018006687A2 (pt) | 2018-10-09 |
| AU2016331314A1 (en) | 2018-05-17 |
| JP2018529779A (ja) | 2018-10-11 |
| IL258476A (en) | 2018-06-28 |
| IL258476B (en) | 2022-12-01 |
| WO2017059451A1 (en) | 2017-04-06 |
| CO2018004576A2 (es) | 2018-07-19 |
| CN108430466A (zh) | 2018-08-21 |
| CA3000842A1 (en) | 2017-04-06 |
| IL258476B2 (en) | 2023-04-01 |
| AU2021205027A1 (en) | 2021-08-12 |
| EP3355879A4 (en) | 2019-05-22 |
| KR20180098222A (ko) | 2018-09-03 |
| HK1259031A1 (zh) | 2019-11-22 |
| US10537541B2 (en) | 2020-01-21 |
| SG10201913953UA (en) | 2020-03-30 |
| US20200046669A1 (en) | 2020-02-13 |
| CL2018000835A1 (es) | 2018-09-14 |
| EP3355879A1 (en) | 2018-08-08 |
| US20170095437A1 (en) | 2017-04-06 |
| EA201890859A1 (ru) | 2018-11-30 |
| US20220000824A1 (en) | 2022-01-06 |
| CN113440506A (zh) | 2021-09-28 |
| IL297844A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004043A (es) | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. | |
| BR112018010650A2 (pt) | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal | |
| EA201792354A1 (ru) | Композиции обетихолевой кислоты и способы применения | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| EA201691940A1 (ru) | Новые соединения | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA201890767A1 (ru) | C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| EA201790817A1 (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера | |
| EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| EA201890878A1 (ru) | Способ лечения медуллобластомы с помощью ингибитора ezh2 | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| EA201492279A1 (ru) | Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек | |
| RU2018124487A (ru) | Лечение внутрипеченочного холестаза и родственных заболеваний печени | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| EA201890862A1 (ru) | Ингибиторы плазменного калликреина человека | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) |